Genmab A (GMAB) Selling, General & Administrative (2018 - 2026)
Powered by 
Analysis
Genmab A (GMAB) Selling, General & Administrative (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | SG&A (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | 1.75 Bn |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | 1.92 Bn |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | 582.20 Mn |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | 662.10 Mn |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | 216.00 Mn |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | -417.00 Mn |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | 347.92 Mn |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | 709.70 Mn |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | 165.53 Mn |
| 10 | Genmab A | 2.23 Bn | 728.64 Mn | 1.07 Bn | -205.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -205.00 Mn |
| Mar 31, 2026 | -166.00 Mn |
| Sep 30, 2025 | -418.00 Mn |
| Jun 30, 2025 | -270.00 Mn |
| Mar 31, 2025 | -126.00 Mn |
| Dec 31, 2024 | -549.00 Mn |
| Sep 30, 2024 | -370.00 Mn |
| Jun 30, 2024 | -243.00 Mn |
| Mar 31, 2024 | -125.00 Mn |
| Dec 31, 2023 | -478.00 Mn |
| Sep 30, 2023 | -839.00 Mn |
| Jun 30, 2023 | -78.66 Mn |
| Jun 30, 2022 | -64.53 Mn |
| Dec 31, 2021 | -29.83 Mn |
| Sep 30, 2021 | -306.00 Mn |
| Jun 30, 2021 | -31.35 Mn |
| Dec 31, 2020 | -20.79 Mn |
| Sep 30, 2020 | -145.00 |
| Jun 30, 2020 | -18.48 Mn |
| Dec 31, 2019 | -81.00 |